Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Sarcoma 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Liposarcoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiotherapy 11Cisplatin 10Paclitaxel 9pembrolizumab 7Fluorouracil 7Oxaliplatin 6Irinotecan 6tislelizumab 5Cetuximab 5Docetaxel 4Radiation 3Nivolumab 3Leucovorin 3Carboplatin 3Capecitabine 3Neoadjuvant Therapy 2Immunohistochemistry 2Biopsy 210-propargyl-10-deazaaminopterin 2tremelimumab 1sitravatinib 1sintilimab 1regorafenib 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1oblimersen 1durvalumab 1cixutumumab 1adavosertib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Squamous Cell Carcinoma × sitravatinib × Clear all
NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

BeiGene

Phase 2 Terminated
96 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡